Shares of PAREXEL International Co. (NASDAQ:PRXL) have earned a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $80.76.

Separately, Zacks Investment Research upgraded PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 target price on the stock in a report on Thursday, August 31st.

A number of large investors have recently added to or reduced their stakes in PRXL. Public Employees Retirement System of Ohio raised its position in PAREXEL International by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 73 shares during the period. Oregon Public Employees Retirement Fund raised its position in PAREXEL International by 1.5% in the second quarter. Oregon Public Employees Retirement Fund now owns 18,820 shares of the medical research company’s stock valued at $1,636,000 after purchasing an additional 283 shares during the period. LS Investment Advisors LLC raised its position in PAREXEL International by 15.6% in the second quarter. LS Investment Advisors LLC now owns 4,182 shares of the medical research company’s stock valued at $363,000 after purchasing an additional 563 shares during the period. Aperio Group LLC raised its position in PAREXEL International by 17.1% in the second quarter. Aperio Group LLC now owns 12,452 shares of the medical research company’s stock valued at $1,082,000 after purchasing an additional 1,816 shares during the period. Finally, State Treasurer State of Michigan raised its position in PAREXEL International by 1.0% in the second quarter. State Treasurer State of Michigan now owns 20,900 shares of the medical research company’s stock valued at $1,816,000 after purchasing an additional 200 shares during the period. 87.45% of the stock is currently owned by institutional investors.

Shares of PAREXEL International (NASDAQ PRXL) traded down $0.02 during trading on Monday, reaching $88.08. The company had a trading volume of 7,021,100 shares, compared to its average volume of 1,041,144. PAREXEL International has a 52-week low of $51.16 and a 52-week high of $88.10. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.45 and a current ratio of 1.45.

PAREXEL International (NASDAQ:PRXL) last issued its earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. The firm had revenue of $557.20 million for the quarter, compared to analysts’ expectations of $537.59 million. During the same quarter last year, the firm earned $0.94 earnings per share.

TRADEMARK VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/11/30/brokerages-set-parexel-international-co-prxl-pt-at-80-76.html.

PAREXEL International Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Analyst Recommendations for PAREXEL International (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with MarketBeat.com's FREE daily email newsletter.